Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Benitec Biopharma Limited (BNTC) had Return on Tangible Equity of -46.04% for the most recently reported fiscal year, ending 2024-06-30.
| Income Statement Financials | |
-- |
|
$-22.37M |
|
$-0.11M |
|
$0.11M |
|
$22.49M |
|
$-22.49M |
|
$0.74M |
|
$-21.75M |
|
$-21.75M |
|
$-21.75M |
|
$-21.75M |
|
$-21.75M |
|
$-21.75M |
|
$-22.49M |
|
$-22.40M |
|
4.06M |
|
4.06M |
|
$-5.51 |
|
$-5.51 |
|
| Balance Sheet Financials | |
$51.67M |
|
$0.18M |
|
$0.54M |
|
$52.21M |
|
$4.92M |
|
-- |
|
$0.04M |
|
$4.96M |
|
$47.25M |
|
$47.25M |
|
$47.25M |
|
10.09M |
|
| Cash Flow Statement Financials | |
$-19.40M |
|
$-0.18M |
|
$68.03M |
|
$2.49M |
|
$50.93M |
|
$48.44M |
|
$0.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.49 |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-19.58M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-46.04% |
|
|
Return on Tangible Equity |
-46.04% |
-41.66% |
|
-46.04% |
|
$4.68 |
|
$-4.82 |
|
$-4.78 |
|